Alimentary Pharmacology & Therapeutics · 1995 · 104 citations · 16 references
MedicineClinical SciencesPharmacotherapyClinical PharmacologyGastroenterologyGastrointestinal PharmacotherapyGastric DiseasesGastric DisordersGastroesophageal Reflux DiseaseGastrointestinal PharmacologyAdverse Drug EventsAntacid TherapyGastroesophageal Reflux Disease PharmacotherapyPeptic EsophagitisPharmacologic Therapy For GerdProton Pump InhibitionReflux EsophagitisSerious Adverse Events
BACKGROUND: Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity. The aim of this study was to compare lansoprazole to a standard dose of ranitidine in the treatment of patients with reflux oesophagitis. METHODS: Two hundred and forty-seven patients with erosive oesophagitis were randomly assigned to 8 weeks of treatment with either 30 mg lansoprazole once daily or 150 mg ranitidine twice daily. RESULTS: Two hundred and forty-two patients were included in the analysis. Lansoprazole (30 mg) daily, healed oesophagitis in 92.1% of patients after 8 weeks of treatment. This was significantly superior to 150 mg ranitidine b.d.s. which healed oesophagitis in 69.9% of patients (P < 0.001). Relief of reflux symptoms was superior with lansoprazole to that with ranitidine. Both lansoprazole and ranitidine were well tolerated with no serious drug-related adverse events noted. CONCLUSION: Lansoprazole, 30 mg once daily, is highly effective and safe in the short-term treatment of erosive oesophagitis.
16
Pathogenesis of Reflux Esophagitis
Wylie J. Dodds, Walter J. Hogan, James F. Helm et al. · Gastroenterology · 1981 · 335 citations
Role of acid and pepsin in acute experimental esophagitis.
Henry I. Goldberg, Wylie J. Dodds, Sheldon Gee et al. · PubMed · 1969 · 211 citations
Role of Acid and Pepsin in Acute Experimental Esophagitis
Henry I. Goldberg, Wylie J. Dodds, Sheldon Gee et al. · Gastroenterology · 1969 · 205 citations · Full text
Lee B. Barradell, Diana Faulds, Donna McTavish · Drugs · 1992 · 162 citations